IL2 and melanoma: Of these therapies, the most widely studied is the use of in vivo γδ T cells activated with zoledronate and/or IL-2, with or without letrozole as an adjunct, for use in prostate, renal cell, and breast cancers, as well as melanoma and neuroblastoma [12, 172–178].